地塞米松联合重组人白介素11治疗初诊原发免疫性血小板减少症的近期疗效观察

Short-term Efficacy of Dexamethasone Combined With Recombinant Human Interleukin-11 in the Treatment of Newly Diagnosed Primary Immune Related Thrombocytopenia

目的观察地塞米松联合重组人白介素-11(rh IL-11)治疗初诊原发免疫性血小板减少症(ITP)的近期疗效。方法 43例患者分为观察组和对照组,治疗后观察疗效及药物不良反应。结果观察组与对照组总有效率对比,差异无统计学意义,外周血小板达峰值时间,观察组短于对照组。常见不良反应两组比较,差异无统计学意义。结论地塞米松联合rhIL-11治疗初诊ITP,短期疗效显著,安全可靠。

Objective To observe the short-term effects of dexamethasone combined with rhIL-11 in treatment of newly diagnosed ITP.Methods 43 cases of patients were divided into the observation group and the control group. The therapeutic effects and the drug adverse effects were observed respectively.Results The total response rate was not signiifcantly different. In the time of BPC ascending to the peak was significantly different between two groups. The side effects were not significantly different. Conclusion The treatment of newly diagnosed ITP with dexamethasone combined rhIL-11 could results in better short-term therapeutic effects and security.